Annual Report: Scrip Asia 100

It is generally agreed that the pandemic accelerated the adoption of decentralized and hybrid clinical trials and according to many commentators they are here to stay. Many countries in Asia appear to be open to the use of these models, however regulatory authorities are looking to other regions to see how they are responding before issuing new guidance. Pharma and biotech organizations in Asia are looking to CROs for practical guidance on how to conduct these clinical trials and exploring what is possible in different countries. Anecdotally, it appears that investigative sites are already getting ready for the changes they will need to make to manage clinical trials that have decentralized components, such as some patient visits being conducted at home or in a convenient location.